Aetion

eBook: The role of RWE in regulatory approvals. Download here.

Aetion real-world data and covid-19 icon

COVID-19 conversation and collaboration

Aetion is committed to advancing COVID-19 research through our work with industry, including FDA, biopharma, and working groups such as the COVID-19 Evidence Accelerator. This page features a snapshot of our and our collaborators’ latest thinking on how real-world data can inform understanding of and response to coronavirus disease.

Usage of medications in-hospital

This chart—generated in Real-Time Insights and Evidence, a solution powered by Aetion and HealthVerity—shows U.S. hospital visits over time, with corresponding use of common medicines used to treat COVID-19.

https://aetion.com/wp-content/uploads/2021/06/Screen-Shot-2021-06-21-at-8.28.40-AM.png

Latest news

July 22, 2021

Research spotlight: Gilead Sciences and Aetion use RWE to assess the comparative effectiveness of remdesivir for COVID-19
April 8, 2021

Research spotlight: Using RWE to assess molecular insights, published in Science
March 18, 2021

Research spotlight: Using RWD to evaluate risk of COVID-19 reinfection
March 4, 2021

How RWE can support drug development during COVID-19 and beyond: Q&A with Dr. Diana Brainard of Gilead Sciences
February 25, 2021

How RWE can advance understanding of—and boost public confidence in—COVID-19 vaccine safety
February 24, 2021

Coronavirus infection leads to immunity that’s comparable to a COVID-19 vaccine

Los Angeles Times

See more news

Real-Time Insights & Evidence

A COVID-ready solution powered by Aetion and HealthVerity

Learn more

The Evidence Digest

Subscribe to our newsletter for insights and updates on research and applications for real-world evidence in life sciences and value-based health care.

arrowcalendarchevronclosecollapsecountdownfacebookflickrinstagramlinelinkedinlocationpinsearchsocialtwitteryoutube